Skip to main content Skip to main navigation menu Skip to site footer

A review of monkeypox: prevention and treatment

  • Stefanus Soewito Sutanto ,
  • Ketut Kwartantaya Winaya ,
  • Luh Made Mas Rusyati ,
  • Pande Agung Mahariski ,

Abstract

Monkeypox (mpox), part of orthopoxvirus, is a viral zoonosis that broke out outside Africa in 2022 and has become a global health concern. Most of the cases are affected by the gay or bisexual community. It can be transmitted from animal to human or between humans. The most common symptoms of monkeypox are fever, lethargy, myalgia, headache, and lymphadenopathy. The most accurate and sensitive diagnostic assay is real-time polymerase chain reaction (PCR). Two types of vaccine can be used to prevent orthopoxvirus: 1) live and non-replicating vaccine (JYNNEOS®) and 2) live replicating vaccinia virus vaccine (ACAM2000®). Monkeypox is a self-limiting disease and only needs symptomatic medication, for individuals with immunocompromised conditions or severe monkeypox infection can be given antivirus such as cidofovir, brincidofovir, and tecovirimat. This review will explain monkeypox treatment and prevention.

References

  1. Kementrian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Penyakit Monkeypox [Internet]. Jakarta; 2022 [cited 2023 May 19]. Available from: https://infeksiemerging.kemkes.go.id/document/download/5qo6p2jOp2
  2. Pan American Health Organization. Guidance on Clinical Suspicion and Differential Diagnosis of Monkeypox [Internet]. 2022. Available from: https://www.who.int/publications/i/item/WHo-Mpx-clinical-and-ipc-2022.1.
  3. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl Trop Dis [Internet]. 2022 Feb 1 [cited 2023 May 19];16(2). Available from: https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0010141&type=printable
  4. Kaler J, Hussain A, Flores G, Kheiri S, Desrosiers D. Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation. Cureus. 2022 Jul 3;
  5. World Health Organization. Mpox (Monkeypox) [Internet]. 2023 [cited 2023 May 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox
  6. CDC. 2022 Mpox Outbreak Global Map [Internet]. CDC. 2023 [cited 2023 May 25]. Available from: https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html
  7. Kaler J, Hussain A, Flores G, Kheiri S, Desrosiers D. Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation. Cureus. 2022 Jul 3;
  8. Lansiaux E, Jain N, Laivacuma S, Reinis A. The virology of human monkeypox virus (hMPXV): A brief overview. Virus Res. 2022 Dec 1;322.
  9. de Sousa D, Frade J, Patrocínio J, Borges-Costa J, Filipe P. Monkeypox infection and bacterial cellulitis: a complication to look for. International Journal of Infectious Diseases. 2022 Oct 1;123:180–2.
  10. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. New England Journal of Medicine. 2022 Aug 25;387(8):679–91.
  11. M. McCollum A, K. Damon I. Human Monkeypox. Clinical Infectious Diseases. 2009 Jan 1;48(1).
  12. Rao AK, Petersen BW, Whitehill ; Florence, Razeq JH, Isaacs SN, Merchlinsky MJ, et al. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices-United States, 2022 [Internet]. 2022. Available from: https://www.cdc.gov/vaccines/acip/recs/grade/JYNNEOS-orthopoxvirus-
  13. Meo SA, Al-Masri AA, Klonoff DC, Alshahrani AN, Al-khlaiwi T. Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications and Adverse Effects of JYNNEOS and ACAM2000 Monkeypox Vaccines. Vaccines (Basel). 2022 Nov 1;10(11).
  14. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and Treatment of Monkeypox. Drugs. 2022 Jun 1;82(9):957–63.
  15. Siegrist EA, Sassine J. Antivirals With Activity Against Mpox: A Clinically Oriented Review. Vol. 76, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. NLM (Medline); 2023. p. 155–64.
  16. DeLaurentis CE, Kiser J, Zucker J. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus. Vol. 66, Antimicrobial Agents and Chemotherapy. American Society for Microbiology; 2022.
  17. CDC. Guidance for Tecovirimat Use [Internet]. CDC. 2023 [cited 2023 May 25]. Available from: https://www.cdc.gov/poxvirus/mpox/clinicians/Tecovirimat.html
  18. Jaiswal V, Nain P, Mukherjee D, Joshi A, Savaliya M, Ishak A, et al. Symptomatology, prognosis, and clinical findings of Monkeypox infected patients during COVID-19 era: A systematic-review. Immun Inflamm

How to Cite

Sutanto, S. S., Winaya, K. K., Rusyati, L. M. M., & Mahariski, P. A. (2023). A review of monkeypox: prevention and treatment. Intisari Sains Medis, 14(2), 961–964. https://doi.org/10.15562/ism.v14i2.1744

HTML
0

Total
0

Share

Search Panel

Stefanus Soewito Sutanto
Google Scholar
Pubmed
ISM Journal


Ketut Kwartantaya Winaya
Google Scholar
Pubmed
ISM Journal


Luh Made Mas Rusyati
Google Scholar
Pubmed
ISM Journal


Pande Agung Mahariski
Google Scholar
Pubmed
ISM Journal